Tag: gastric cancer industry trends

Uncover key drivers, emerging technologies, and competitive movements shaping the gastric cancer market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Gastric Cancer Market expected to reach by 2030?

The gastric cancer market size has experienced rapid growth in recent years. It is set to expand from $3.64 billion in 2025 to $4.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.2%. The historical increase can be ascribed to a significant prevalence of helicobacter pylori infection, smoking, and dietary risk factors, alongside the broadening use of chemotherapy, the development of hospital-based oncology care, and progress in surgical oncology.

The gastric cancer market is projected for significant expansion in the coming years. By 2030, this market is anticipated to reach $7.29 billion, demonstrating a compound annual growth rate (CAGR) of 14.8%. This expansion during the forecast period can be ascribed to progress in immuno-oncology, the development of precision diagnostics, the proliferation of cancer screening initiatives, an expanding aging demographic, and the creation of innovative targeted medications. Key trends anticipated for this period involve the increasing uptake of targeted and immunotherapies, a heightened emphasis on early diagnosis and screening, the broadening of personalized cancer treatment strategies, greater application of combination therapy protocols, and enhanced multidisciplinary cancer care frameworks.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

What Drivers Are Driving Adoption Within The Gastric Cancer Market?

The growth of the gastric cancer market is expected to be propelled by increasing obesity rates. Obesity is a medical condition marked by excessive body fat accumulation, commonly defined by a body mass index (BMI) of 30 or higher, which can lead to various health issues. The rise in obesity rates is attributed to factors like poor diet, lack of physical activity, sedentary lifestyles, environmental influences, and genetic predispositions. Excess body fat, particularly visceral fat around the abdomen, is associated with a higher risk of developing gastric cancer, as obesity triggers chronic inflammation and metabolic disturbances, both linked to cancer development, thereby contributing to a rise in the demand for gastric cancer treatment. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that one in eight people worldwide now live with obesity, exceeding 1 billion individuals. Consequently, the rising obesity rates are driving the gastric cancer market.

What Segments Are Included Within The Gastric Cancer Market?

The gastric cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis

3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

Which Market Trends Are Opening Growth Opportunities In The Gastric Cancer Market?

Leading companies in the gastric cancer market are dedicating efforts to developing advanced technological solutions, such as companion diagnostic assays, to facilitate personalized treatment. A companion diagnostic assay is a diagnostic tool employed to identify patients most likely to benefit from a specific therapeutic intervention based on the presence of particular biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical entity, announced that the U.S. Food and Drug Administration (FDA) had approved its VENTANA CLDN18 (43-14A) RxDx Assay. This represents the inaugural immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in adenocarcinoma of the stomach and gastroesophageal junction (GEJ). This assay is designed to identify patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18. 2. By utilizing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test significantly advances personalized healthcare and expands the treatment options available for gastric and GEJ adenocarcinoma.

Who Are The Top-Performing Companies In The Gastric Cancer Market In Recent Years?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Taiho Oncology Inc., Taiho Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biocon Limited, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastric Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Market 2026, By The Business Research Company

Esophageal Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Ulcers Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Gastric Cancer Market?

In the past few years, the gastric cancer market has seen exponential growth. The market, which is estimated to be worth $3.17 billion in 2024, is projected to increase to $3.64 billion in 2025 with a compound annual growth rate (CAGR) of 14.8%. The expansion observed in the historical era is attributable to an aging population, heightened health conscious behavior, growth in genetic mutations, a surge in unhealthy lifestyle practices, and an increase in cancer awareness.

In the coming years, the market size for gastric cancer is projected to experience quick expansion. It is anticipated to reach $6.37 billion in 2029, with a compound annual growth rate (CAGR) of 15.0%. The hike during the forecasted period could be due to factors such as increased obesity rates, comprehensive government initiatives, heightened investments in healthcare, growing demand for oral medications, and an uptick in cancer treatment facilities. Key trends for the forecast period involve combination chemotherapy, product enlargement, robotic-assisted surgeries, targeted treatments, strategic partnerships, and cutting-edge diagnostic instruments.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Gastric Cancer Market?

Increasing rates of obesity globally are predicted to stimulate the expansion of the gastric cancer market. Classified by a BMI (body mass index) of 30 or higher, obesity is a health condition marked by the excessive accumulation of body fat. It may cause a myriad of health complications and is on the rise due to factors such as unhealthy diet, sedentary behavior, environmental factors, insufficient physical exercise, and genetic predispositions. Notably, excessive body fat, especially visceral fat around the abdomen, increases the risk of stomach cancer because it triggers persistent inflammation and metabolic imbalances, which are both linked to cancer onset. This, in turn, boosts the demand for treatments for stomach cancer. As an example, in March 2024, the Switzerland-based intergovernmental body, the World Health Organization, reported that approximately 1 in 8 people worldwide had obesity in 2022. This figure included 2.5 billion adults aged 18 and up who were branded as overweight, with 890 million of those having obesity. Among adults, 43% were described as overweight and 16% as obese. Also, 37 million children below the age of 5 were overweight, and over 390 million children and adolescents between the ages of 5 and 19 were overweight, with 160 million of these being obese. Consequently, the upsurge in obesity rates is propelling the stomach cancer market.

What Are The Key Segment Trends Observed In The Gastric Cancer Market?

The gastric cancermarket covered in this report is segmented –

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types

2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis

3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

Which Disruptive Trends Are Driving Change Across The Gastric Cancer Market?

Leading firms active in the gastric cancer market are investing in the creation of cutting-edge solutions, such as companion diagnostic assays, to enable personalized treatment. Companion diagnostic assays are tests designed to find patients who stand to benefit the most from a particular therapy, depending on the existence of specific biomarkers. For illustration, F. Hoffmann-La Roche Ltd., a pharmaceutical company hailing from Switzerland, announced in October 2024 that it had received approval by the U.S. Food and Drug Administration (FDA) for its VENTANA CLDN18 (43-14A) RxDx Assay. This assay is the first immunohistochemistry (IHC) companion diagnostic for evaluating CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. It helps identify those suitable for targeted VYLOY (zolbetuximab) treatment by measuring types of the CLDN18 protein, primarily CLDN18.2. Employing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test enhances personalized healthcare and widens the treatment scope for gastric and GEJ adenocarcinoma.

Who Are The Leading Companies Driving The Gastric Cancer Market?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Which Region Is Forecasted To Lead The Gastric Cancer Market In The Coming Years?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Gastric Cancer Market Over The Five-Year Period 2025–2029?

The gastric cancer market has shown significant growth in recent years. This market is anticipated to expand from $3.17 billion in 2024 to $3.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.8%. The historical growth is linked to factors including an increasing elderly population, enhanced healthcare awareness, more frequent genetic mutations, the growing trend of unhealthy lifestyles, and improved cancer awareness.

The market for gastric cancer treatments is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $6.37 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.0%. Several factors are driving this anticipated growth, including a rise in obesity, expanding government initiatives, greater investments in healthcare, a heightened demand for oral medications, and an increasing availability of cancer treatment centers. Key developments expected during this period involve the adoption of combination chemotherapy, broadening product offerings, the use of robotic-assisted surgery, the development of targeted therapies, collaborative strategies, and more sophisticated diagnostic instruments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Drivers Are Shaping The Gastric Cancer Industry’s Market Share?

The future expansion of the gastric cancer market is anticipated due to increasing obesity rates. Obesity is a medical condition characterized by excessive body fat accumulation, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health problems. Obesity rates are rising due to factors such as poor diet, lack of physical activity, sedentary lifestyles, environmental influences, and genetic predispositions. Excess body fat, particularly visceral fat around the abdomen, is associated with a higher risk of developing gastric cancer as obesity triggers chronic inflammation and metabolic disturbances, both linked to cancer development, contributing to a rise in the demand for gastric cancer treatment. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 1 in 8 people globally were living with obesity in 2022, with 2.5 billion adults aged 18 and older classified as overweight, including 890 million individuals living with obesity. Among adults, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight, while over 390 million children and adolescents aged 5–19 years were overweight, including 160 million living with obesity. Therefore, the rising obesity rates are driving the gastric cancer market.

What Are The Emerging Segments Gaining Attention In The Gastric Cancer Market?

The gastric cancermarket covered in this report is segmented –

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types

2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis

3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

What Are The Latest Industry Trends Transforming The Gastric Cancer Market?

Leading companies in the gastric cancer market are concentrating on creating technologically advanced solutions, including companion diagnostic assays, to facilitate personalized treatment. A companion diagnostic assay is a test utilized to identify patients who are most likely to gain from a specific therapeutic treatment based on the presence of certain biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its VENTANA CLDN18 (43-14A) RxDx Assay, which stands as the initial immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. This assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. Employing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test propels personalized healthcare forward, thereby broadening the treatment choices for gastric and GEJ adenocarcinoma.

Who Are The Core Companies Influencing The Gastric Cancer Market Landscape?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Which Region Currently Holds The Largest Share Of The Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastric Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Gastric Cancer Market From 2025 To 2029?

The market size for gastric cancer has seen a swift expansion in the latest years. It is predicted to increase from $3.17 billion in 2024 to $3.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.8%. The previous growth can be traced back to factors such as the burgeoning population of the elderly, amplified healthcare cognizance, augmenting genetic mutations, a surge in the adoption of unhealthy lifestyle habits, and a heightening awareness about cancer.

Expectations are high for swift expansion in the gastric cancer market in the coming years. The market is projected to surge to a value of$6.37 billion by 2029″ with a robust compound annual growth rate (CAGR) of 15.0%. This projected growth within the forecast period can be associated with factors such as the rising obesity problem, growing government initiatives, increased investments in healthcare, escalating demand for oral cancer drugs, and a rising number of specialist facilities for cancer treatment. The forecast period is also expected to witness significant trends including combination chemotherapy, expansion of products, the use of robotic-assisted surgery, targeted therapies, strategic collaborations, and advanced diagnostic tools.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Gastric Cancer Market?

The surge in obesity rates is predicted to fuel the expansion of the gastric cancer market in the future. Obesity, a medical issue marked by excessive fat accumulation in the body, is usually identified by a body mass index (BMI) above 30, resulting in various health problems. The increase in obesity instances can be attributed to factors including poor nutrition, inactivity, sedentary lifestyles, environmental factors, and genetic propensities. Excess body fat, especially abdominal visceral fat, is associated with an increased risk of gastric cancer because obesity leads to persistent inflammation and metabolic disorders, both of which can lead to cancer, thereby increasing the need for gastric cancer therapies. For instance, according to the Switzerland-based World Health Organization’s March 2024 report, approximately one in eight people worldwide were categorized as obese in 2022. The report revealed that 2.5 billion adults aged 18 and over fell into the overweight category, with 890 million suffering from obesity. The data showed that 43% of adults were overweight, and 16% were classified as obese. Additionally, 37 million children below the age of 5 were overweight, and more than 390 million children and adolescents between the ages of 5 and 19 fell into the overweight category, including 160 million living with obesity. As a result of the increasing obesity rates, the gastric cancer market is experiencing a boost in its demand.

Which Key Market Segments Comprise the Gastric Cancer Market and Drive Its Revenue Growth?

The gastric cancermarket covered in this report is segmented –

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types

2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis

3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Which Areas Are Leading Regions in the Gastric Cancer Market Expansion Across the Globe?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theGastric Cancer Market Over the Coming Years?

Market-dominant businesses within the gastric cancer sector are concentrating their efforts on devising innovative and tech-savvy solutions such as companion diagnostic assays. These are tests designed to single out patients most likely to respond positively to a specific therapy based on the detection of certain biomarkers. One such case is of F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland. They announced in October 2024, the approval of VENTANA CLDN18 (43-14A) RxDx Assay by the U.S. Food and Drug Administration (FDA). This assay is the first immunohistochemistry (IHC) companion diagnostic for measuring CLDN18 protein expression, primarily CLDN18.2, in gastric and gastroesophageal junction (GEJ) adenocarcinoma. It helps identify patients suitable for targeted treatment with VYLOY (zolbetuximab). With the use of the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test propels personalized healthcare, paving the way for expanded treatment methods for gastric and GEJ adenocarcinoma.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

How Is the Gastric Cancer Market Conceptually Defined?

Gastric cancer is a malignant tumor that originates in the lining of the stomach. It often begins in the mucosa, the innermost layer of the stomach, and can spread to deeper layers, nearby tissues, or distant organs if not treated early. The disease is commonly associated with risk factors such as chronic infection with helicobacter pylori, smoking, excessive alcohol consumption, poor diet, and genetic predisposition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Gastric Cancer Market Growth in 2025?

There has been a swift expansion in the size of the gastric cancer market in the past few years. Projected to increase from $3.17 billion in 2024 to $3.65 billion in 2025, the market is expected to witness a compound annual growth rate (CAGR) of 15.4%. The previous growth can be credited to factors such as the swelling geriatric population, escalating healthcare consciousness, the multiplying instances of genetic mutations, the growing preference for unhealthy lifestyles, and heightened awareness about cancer.

What Is the Forecast for the Gastric Cancer Market Size Through 2029?

In the coming years, the market size for gastric cancer is anticipated to experience swift expansion. By 2029, it is predicted to reach $6.43 billion, with a Compound Annual Growth Rate (CAGR) of 15.2%. The expansion during this projected period is credited to factors such as rising obesity rates, expanding government programs, increased investment in healthcare, growing requirement for oral medications, and an upsurge in the number of cancer treatment centers. The key market trends to look out for during this period include combined chemotherapy, product diversification, robot-assisted surgeries, specialized therapies, strategic partnerships, and advanced diagnostic tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

What are the Key Market Players in Gastric Cancer Market and How They’re Evolving?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Gastric Cancer Market?

The growth of the gastric cancer market is anticipated to be fueled by increasing obesity incidences. Obesity, a health condition marked by an excessive accumulation of body fat and typically identified by a body mass index (BMI) of 30 or more, can lead to a range of health complications. The increase in obesity cases can be attributed to various factors like inadequate diet, absence of physical activity, sedentary lifestyles, environmental influences, and genetic factors. Excessive body fat, especially the visceral fat present around the abdomen, carries a higher risk of gastric cancer as it incites persistent inflammation and metabolic disruptions which are linked to the development of cancer, thereby leading to a surge in the need for gastric cancer treatment. For example, in March 2024, the World Health Organization, an intergovernmental organization based in Switzerland, reported that in 2022, approximately 1 in 8 people worldwide were obese, with roughly 2.5 billion adults aged 18 and over classified as overweight, which includes 890 million individuals who were obese. In the adult population, 43% were overweight and 16% were obese. In addition, 37 million children below the age of 5 were overweight and over 390 million children and young people aged between 5 and 19 were overweight, of which 160 million were obese. Consequently, the increasing obesity rates are fueling the growth of the gastric cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

What Are the Leading Segments in the Global Gastric Cancer Industry?

The gastric cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis

3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

What Are the Key Market Trends in the Gastric Cancer Industry?

Top-tier companies in the gastric cancer market place a strong emphasis on the development of technologically progressive solutions such as companion diagnostic assays. These assays are employed to pinpoint patients likely to gain the most from specific therapeutic treatments, by detecting certain biomarkers. An example of this came to light in October 2024, when F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, revealed they had received approval from the U.S. Food and Drug Administration (FDA) for their product, VENTANA CLDN18 (43-14A) RxDx Assay. This was the premier immunohistochemistry (IHC) companion diagnostic used for evaluating CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. By assessing CLDN18 protein variants, this assay identifies patients suitable for targeted treatment with VYLOY (zolbetuximab), specifically the CLDN18.2 variant. Using the OptiView DAB IHC Detection Kit on the BenchMark ULTRA system, the test propels personalized healthcare forward, broadening available treatment methods for gastric and GEJ adenocarcinoma.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

What Is the Regional Outlook for the Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

This Report Delivers Insight On:

1. How big is the gastric cancer market, and how is it changing globally?

2. Who are the major companies in the gastric cancer market, and how are they performing?

3. What are the key opportunities and risks in the gastric cancer market right now?

4. Which products or customer segments are growing the most in the gastric cancer market?

5. What factors are helping or slowing down the growth of the gastric cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Are the Key Milestones in the Gastric Cancer Market’s Growth Trajectory From 2025 To 2034?

The market size for gastric cancer has been expanding swiftly over the past few years. The expectation is for it to escalate from $3.17 billion in 2024 to $3.65 billion in 2025, with a compound annual growth rate (CAGR) of 15.4%. The notable growth during the historical period is linked to the surge in the elderly population, heightened healthcare awareness, the rise of genetic mutations, increased adoption of unhealthy lifestyles and growing consciousness about cancer.

The market size for gastric cancer is predicted to experience a swift expansion in the forthcoming years. The market value is set to reach $6.43 billion by 2029, with a compound annual growth rate (CAGR) of 15.2%. This growth in the predicted period can be accredited to factors such as rising obesity rates, enhancement in government initiatives, amplified investments in healthcare, a surge in demand for oral medication, an increment in cancer treatment facilities. Key trends expected during the forecast period are combination chemotherapy, product enlargement, robotic-aided surgeries, targeted treatment methods, strategic cooperation, and sophisticated diagnostic tools.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Factors and External Forces Are Driving Demand in the Gastric Cancer Market?

The escalating numbers of obesity is predicted to amplify the expansion of the gastric cancer market moving forward. Obesity, a health disorder marked by excessive accumulation of body fat, often identified by a body mass index (BMI) of 30 or above, can lead to numerous health complications. The increasing prevalence of obesity can be attributed to reasons such as unhealthy food habits, inadequate physical exercise, sedentary way of life, environmental factors, and genetic influences. Excessive body fat, specifically visceral fat around the belly, is related to a heightened risk of gastric cancer as it instigates chronic inflammation and metabolic disturbances, both associated with cancer formation, contributing to a surge in the demand for gastric cancer therapy. For example, in March 2024, the World Health Organization, an Intergovernmental organization based in Switzerland, reported that nearly 1 in 8 individuals worldwide were obese in 2022, with around 2.5 billion adults over the age of 18 characterized as overweight, which includes around 890 million persons with obesity. In adults, 43% were overweight, and 16% were obese. Moreover, 37 million children under 5 were overweight, while over 390 million children and teenagers between 5 and 19 years were overweight or obese, which included 160 million living with obesity. Hence, the upward trend in obesity rates is influencing the growth of the gastric cancer market.

Which Segments in the Gastric Cancer Offer the Most Growth?

The gastric cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis

3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

What Are the Fastest-Growing Geographies in the Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Gastric Cancer Market?

Leading enterprises in the gastric cancer market are striving to create state-of-the-art solutions like companion diagnostic assays. These are aimed at personalizing treatment by helping to pinpoint those who would gain the most from a specific therapy, based on particular biomarkers. An illustration is the announcement by Switzerland’s F. Hoffmann-La Roche Ltd., in October 2024, of their regulatory approval by the U.S. FDA for the VENTANA CLDN18 (43-14A) RxDx Assay. This is the inaugural immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay spots patients eligible for targeted VYLOY (zolbetuximab) treatment as it measures CLDN18 protein variants, especially CLDN18.2. The test, which uses the OptiView DAB IHC Detection Kit on the BenchMark ULTRA device, furthers personalized healthcare and widens therapy alternatives for gastric and GEJ adenocarcinoma.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

What Are the Key Elements That Define the Gastric Cancer Market?

Gastric cancer is a malignant tumor that originates in the lining of the stomach. It often begins in the mucosa, the innermost layer of the stomach, and can spread to deeper layers, nearby tissues, or distant organs if not treated early. The disease is commonly associated with risk factors such as chronic infection with helicobacter pylori, smoking, excessive alcohol consumption, poor diet, and genetic predisposition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model